Vinta Bio

VintaBio is a biotechnology company based in Philadelphia, Pennsylvania. The company employs 14 people and has generated over $10,000 in revenue. VintaBio specializes in developing and manufacturing viral vectors, a crucial component in cell and gene therapy (CGT) development. VintaBio's team boasts over a century of combined experience in the cell and gene therapy space, with members having contributed to the advancement of leading therapies on the market. They focus on providing consistent, high-quality viral vectors, addressing a critical and currently underserved area within CGT development. Founded by Junwei Sun and Dr. Shangzhen Zhou, VintaBio's founders have a proven track record, having led the development of AAV vectors used in the first two FDA-approved gene therapies and the lentiviral vector for the first FDA-approved cell therapy. The company has secured $64 million in venture funding, which has been instrumental in establishing a state-of-the-art, 22,500 square foot facility in Philadelphia dedicated to efficient cell and gene therapy manufacturing. For more information about VintaBio and its services, please visit their website at vintabio.com.